Physical Color Calibration of Digital Pathology Scanners for Robust Artificial Intelligence Assisted Cancer Diagnosis
Authors:
Xiaoyi Ji,
Richard Salmon,
Nita Mulliqi,
Umair Khan,
Yinxi Wang,
Anders Blilie,
Henrik Olsson,
Bodil Ginnerup Pedersen,
Karina Dalsgaard Sørensen,
Benedicte Parm Ulhøi,
Svein R Kjosavik,
Emilius AM Janssen,
Mattias Rantalainen,
Lars Egevad,
Pekka Ruusuvuori,
Martin Eklund,
Kimmo Kartasalo
Abstract:
The potential of artificial intelligence (AI) in digital pathology is limited by technical inconsistencies in the production of whole slide images (WSIs), leading to degraded AI performance and posing a challenge for widespread clinical application as fine-tuning algorithms for each new site is impractical. Changes in the imaging workflow can also lead to compromised diagnoses and patient safety r…
▽ More
The potential of artificial intelligence (AI) in digital pathology is limited by technical inconsistencies in the production of whole slide images (WSIs), leading to degraded AI performance and posing a challenge for widespread clinical application as fine-tuning algorithms for each new site is impractical. Changes in the imaging workflow can also lead to compromised diagnoses and patient safety risks. We evaluated whether physical color calibration of scanners can standardize WSI appearance and enable robust AI performance. We employed a color calibration slide in four different laboratories and evaluated its impact on the performance of an AI system for prostate cancer diagnosis on 1,161 WSIs. Color standardization resulted in consistently improved AI model calibration and significant improvements in Gleason grading performance. The study demonstrates that physical color calibration provides a potential solution to the variation introduced by different scanners, making AI-based cancer diagnostics more reliable and applicable in clinical settings.
△ Less
Submitted 7 July, 2023;
originally announced July 2023.
Identification of a Proliferation Gene Cluster Associated with HPV E6/E7 Expression Level and Viral DNA Load in Invasive Cervical Carcinoma
Authors:
Christophe Rosty,
Michal Sheffer,
Dafna Tsafrir,
Nicolas Stransky,
Ilan Tsafrir,
Martine Peter,
Patricia de Cremoux,
Anne de La Rochefordiere,
Remy Salmon,
Thierry Dorval,
Jean Paul Thiery,
Jerome Couturier,
Francois Radvanyi,
Eytan Domany,
Xavier Sastre-Garau
Abstract:
Specific HPV DNA sequences are associated with more than 90% of invasive carcinomas of the uterine cervix. Viral E6 and E7 oncogenes are key mediators in cell transformation by disrupting TP53 and RB pathways. To investigate molecular mechanisms involved in the progression of invasive cervical carcinoma, we performed a gene expression study on cases selected according to viral and clinical param…
▽ More
Specific HPV DNA sequences are associated with more than 90% of invasive carcinomas of the uterine cervix. Viral E6 and E7 oncogenes are key mediators in cell transformation by disrupting TP53 and RB pathways. To investigate molecular mechanisms involved in the progression of invasive cervical carcinoma, we performed a gene expression study on cases selected according to viral and clinical parameters. Using Coupled Two-Way Clustering and Sorting Points Into Neighbourhoods methods, we identified a Cervical Cancer Proliferation Cluster composed of 163 highly correlated transcripts, many of which corresponded to E2F pathway genes controlling cell proliferation, whereas no primary TP53 targets were present in this cluster. The average expression level of the genes of this cluster was higher in tumours with an early relapse than in tumours with a favourable course (P=0.026). Moreover, we found that E6/E7 mRNA expression level was positively correlated with the expression level of the cluster genes and with viral DNA load. These findings suggest that HPV E6/E7 expression level plays a key role in the progression of invasive carcinoma of the uterine cervix via the deregulation of cellular genes controlling tumour cell proliferation. HPV expression level may thus correspond to a biological marker useful for prognosis assessment and specific therapy of the disease.
△ Less
Submitted 15 November, 2005;
originally announced November 2005.
